Sharp, T., Bramwell, S.R. and Grahame-Smith, D.G. (1989) 5-HT1 Agonists Reduce 5-Hydroxytryptamine Release in Rat Hippocampus in Vivo as Determined by Brain Microdialysis. British Journal of Pharmacology, 96, 283-290.
https://doi.org/10.1111/j.1476-5381.1989.tb11815.x

has been cited by the following article:

• TITLE: Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine

  AUTHORS: Robert B. Raffa, Joseph V. Pergolizzi, Robert Taylor, Robert P. James, Mark Pirner

  KEYWORDS: Lofexidine, Clonidine, Opioid Withdrawal, Receptor Affinity, Alpha-2 Agonist

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.10 No.1, January 3, 2019

  ABSTRACT: Lucemyra? (lofexidine hydrochloride) has recently been approved by the US FDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Lofexidine is an alpha-2 adrenoceptor agonist. However, the clinical attributes of lofexidine differ in advantageous ways from the classical alpha-2 adrenoceptor agonist clonidine. In the present study, we measured the receptor binding profile of lofexidine and clonidine in an effort to gain an insight into the clinical difference(s).